Morphological and morphometric analysis of cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa: a retrospective study

被引:11
|
作者
Filoni, A. [1 ,2 ]
Cicco, G. [1 ]
Lospalluti, L. [1 ]
Maglietta, A. [3 ]
Foti, C. [1 ]
Annichiarico, G. [4 ]
Resta, L. [3 ]
Bonamonte, D. [1 ]
机构
[1] Univ Bari, Sect Dermatol, Dept Biomed Sci & Human Oncol, Bari, Italy
[2] San Gallicano Dermatol Inst IRCCS, Rome, Italy
[3] Univ Bari, Dept Emergency & Organ Transplantat, Sect Pathol, Bari, Italy
[4] AReS Puglia, Reg Coordinat Rare Dis, Bari, Italy
关键词
GROWTH-FACTOR; FORMS; RISK;
D O I
10.1111/jdv.16022
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Recessive dystrophic epidermolysis bullosa is a highly disabling genodermatosis characterized by skin and mucosal fragility and blistering. Cutaneous squamous cell carcinoma (cSCC) is one of the most devastating complications, having a high morbidity and mortality rate. Patients with recessive dystrophic epidermolysis bullosa were reported to have up to a 70-fold higher risk of developing cSCC than unaffected individuals. Immune cells play a role in cancer evolution. Objective The aim of our study was to evaluate immunohistological differences between cSCC in patients with and without recessive dystrophic epidermolysis bullosa. Methods A retrospective study of 25 consecutive cases was performed; five were biopsies of cSCC taken from five patients with recessive dystrophic epidermolysis bullosa; as controls we analysed 10 cSCC in subjects without recessive dystrophic epidermolysis bullosa (5 primitive, 3 postburns and 2 postradiotherapy), 5 cSCC in renal transplant recipients and 5 cutaneous pseudoepitheliomatous hyperplasia in patients with recessive dystrophic epidermolysis bullosa. Results A significant reduction of CD3+, CD4+ and CD68+ between the cSCC in patients with recessive dystrophic epidermolysis bullosa compared to primary cSCC and a significant reduction of CD3+, CD4+, CD8+ and CD20+ were observed in cSCC in patients with recessive dystrophic epidermolysis bullosa compared to secondary cSCC. On the contrary, there was no difference in CD3+, CD8+, CD20+ and CD68+ expression when comparing cSCC in patients with recessive dystrophic epidermolysis bullosa to cSCC in renal transplant recipients. No significant difference was found in size, histopathology, grading, number of mitoses and EGFR expression between the different groups. Conclusions Our data show a reduction in immune cell peritumoral infiltration. Considering the well-known evolution of cSCC in patients with recessive dystrophic epidermolysis bullosa, as well as the younger age at diagnosis, it can be assumed that immune dysfunction might contribute to the cSCC aggressiveness in these patients.
引用
收藏
页码:1707 / 1714
页数:8
相关论文
共 50 条
  • [41] SQUAMOUS-CELL CARCINOMA SECONDARY TO RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA - A REPORT OF 4 PATIENTS WITH 17 PRIMARY CUTANEOUS MALIGNANCIES
    NEWMAN, C
    WAGNER, RF
    TYRING, SK
    SPIGEL, GT
    JOURNAL OF DERMATOLOGIC SURGERY AND ONCOLOGY, 1992, 18 (04): : 301 - 305
  • [42] A cephalometric analysis of patients with recessive dystrophic epidermolysis bullosa
    Shah, H
    McDonald, F
    Lucas, V
    Ashley, P
    Roberts, G
    ANGLE ORTHODONTIST, 2002, 72 (01) : 55 - 60
  • [43] RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA AND MULTIPLE SQUAMOUS-CELL CARCINOMAS
    CARAPETO, FJ
    PASTOR, JA
    MARTIN, J
    AGURRUZA, J
    DERMATOLOGICA, 1982, 165 (01): : 39 - 46
  • [44] Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa
    Krupiczojc, M. A.
    O'Toole, E. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 174 (01) : 15 - 15
  • [45] CUTANEOUS NEOPLASIA IN RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA
    MCKEE, PH
    MAYOU, BJ
    SCHOFIELD, OMV
    EADY, RAJ
    JOURNAL OF PATHOLOGY, 1991, 163 (02): : A183 - A183
  • [46] Cutaneous Squamous Cell Carcinoma in Epidermolysis Bullosa: a 28-year Retrospective Study
    Robertson, Susan J.
    Orrin, Elizabeth
    Lakhan, Manpreet K.
    O'Sullivan, Gavin
    Felton, Jessie
    Robson, Alistair
    Greenblatt, Danielle T.
    Bernardis, Catina
    McGrath, John A.
    Martinez, Anna E.
    Mellerio, Jemima E.
    ACTA DERMATO-VENEREOLOGICA, 2021, 101
  • [47] Dystrophic epidermolysis bullosa complicated by cutaneous squamous cell carcinoma and pulmonary and renal amyloidosis
    Csikós, M
    Orosz, Z
    Bottlik, G
    Szöcs, H
    Szalai, Z
    Rozgonyi, Z
    Hársing, J
    Török, É
    Bruckner-Tuderman, L
    Horváth, A
    Kárpáti, S
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2003, 28 (02) : 163 - 166
  • [48] Recessive dystrophic epidermolysis bullosa and squamous-cell carcinoma: The role of type VII collagen
    Kirsner, Robert S.
    Hu, Shasa
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 (10) : 2292 - 2292
  • [49] MALIGNANT-MELANOMA AND A SQUAMOUS-CELL CARCINOMA IN RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA
    CHORNY, JA
    SHROYER, KR
    GOLITZ, LE
    ARCHIVES OF DERMATOLOGY, 1993, 129 (09) : 1212 - 1212
  • [50] Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma
    Atanasova, Velina S.
    Pourreyron, Celine
    Farshchian, Mehdi
    Lawler, Michael
    Brown, Christian A.
    Watt, Stephen A.
    Wright, Sheila
    Warkala, Michael
    Guttmann-Gruber, Christina
    Hofbauer, Josefina Pinon
    Fuentes, Ignacia
    Prisco, Marco
    Rashidghamat, Elham
    Has, Cristina
    Salas-Alanis, Julio C.
    Palisson, Francis
    Hovnanian, Alain
    McGrath, John A.
    Mellerio, Jemima E.
    Bauer, Johann W.
    South, Andrew P.
    CLINICAL CANCER RESEARCH, 2019, 25 (11) : 3384 - 3391